NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Braveheart Bio

Braveheart Bio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.braveheart.bio/

Last Round

Series A

Nov 5, 2025

Total Funding Raised

$185M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Braveheart Bio is a biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related cardiovascular conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalmyosin inhibitorhypertrophic cardiomyopathyHCMcardiovascular therapeuticsclinical-stage biotechsmall molecule drugdrug developmentclinical trialsin-licensingpharma pipelinebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Braveheart Bio Comps

Public and private peers based on sector, stage, and business model.

Braveheart Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Braveheart Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 5, 2025

Key People

Founding team and executive leadership

Travis Murdoch

CEO and President

Executive Team

Paul Rickey

Chief Financial Officer

Executive Team

Braveheart Bio Investors

Notable investors and investment history

Braveheart Bio investors
InvestorRounds
Andreessen HorowitzSeries A
Enavate SciencesSeries A
ForbionSeries A
OrbiMedSeries A
Frazier Life SciencesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 6, 2026

    Grew 35% QoQ, from 20 to 27 employees.

  • Mar 31, 2026

    Lee Bockus joins as Senior Medical Director.

Braveheart Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Braveheart Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Braveheart Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range36
Year Founded2024
Last FundingNov 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.